Cannabis helps a lot of people get through cancer treatment. That is not the same thing as treating cancer. Almost all the confusion lives in the gap between those two sentences.
Key Takeaways
The evidence for cannabis in cancer care is strongest for symptom management, and weakest exactly where the internet is loudest: killing tumors.
Twenty-five years of laboratory work shows cannabinoids attacking cancer cells in dishes and in mice. In humans, the entire direct anti-tumor record is two small trials.
The 2017 National Academies review found insufficient evidence either to support or refute cannabinoids as a cancer treatment. That has not changed.
ARISTOCRAT, a Phase 2 trial in the UK with overall survival as its primary endpoint, is the study that could move the question. It is still recruiting.
Rick Simpson gave his recipe away and never sold the oil. The cure claim attached to it still has no scientific evidence behind it, and rests on a lesion a surgeon had already removed.
Cancer patients are using cannabis faster than physicians can tell them whether it works.
In 2024, the American Society of Clinical Oncology, the main professional body for cancer doctors in the United States, published its first full guideline on cannabis and cannabinoids in adults with cancer. The panel worked through thirteen systematic reviews and dozens of trials. It opened by conceding the obvious: patient use has run well ahead of the evidence.
Its central recommendation is that cannabis should not be used as cancer-directed treatment, meaning treatment aimed at the tumor itself, outside a clinical trial. On the one hand, there’s a real and growing body of evidence that cannabis helps people endure cancer and its treatment. On the other, a claim that has circulated for two decades with almost nothing behind it.
What the Evidence Supports
Solid …
Read More
Author: Rolando García / High Times
